No abuse potential shown in preclinical studies
We are delighted to share promising preclinical results for our innovative drug candidate PN6047, further confirming its safety profile. PN6047 is designed to provide relief from neuropathic pain, and these findings reinforce our commitment to safe and effective pain management as we prepare for Phase II trials in 2024.
Key outcomes from the preclinical studies:
- No abuse potential: PN6047 displayed no signs of abuse potential in animal models, marking a notable departure from conventional opioids.
- Alleviates the opioid withdrawal syndrome: PN6047 mitigated symptoms associated with opioid withdrawal in animal models.
These studies, conducted in collaboration with Washington University and the University of Michigan and supported by the US National Institute of Drug Abuse, represent a significant step forward in our mission to provide safe and effective pain relief without the risk of addiction or severe side effects. As we gear up for Phase II clinical trials in 2024, our commitment to redefining pain management remains unwavering.
No abuse potential shown in preclinical studies
We are delighted to share promising preclinical results for our innovative drug candidate PN6047, further confirming its safety profile. PN6047 is designed to provide relief from neuropathic pain, and these findings reinforce our commitment to safe and effective pain management as we prepare for Phase II trials in 2024.
Key outcomes from the preclinical studies:
- No abuse potential: PN6047 displayed no signs of abuse potential in animal models, marking a notable departure from conventional opioids.
- Alleviates the opioid withdrawal syndrome: PN6047 mitigated symptoms associated with opioid withdrawal in animal models.
These studies, conducted in collaboration with Washington University and the University of Michigan and supported by the US National Institute of Drug Abuse, represent a significant step forward in our mission to provide safe and effective pain relief without the risk of addiction or severe side effects. As we gear up for Phase II clinical trials in 2024, our commitment to redefining pain management remains unwavering.
Latest news
View all
Positive final Phase I results
The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.
Read more
Meet Bengt von Mentzer, founder and Chief scientific advisor
Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.
Read more
NIDA funds studies
The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.
Read more
Meet Olof Breuer, MD, Clinical pharmacology lead
Olof Breuer's presence at PharmNovo exemplifies the company's commitment to pioneering advancements in pain relief. His visionary approach, honed through years of experience, positions him as a driving force in the quest for novel concepts in neuropathic pain relief.
Read more